Amgen (AMGN) – Press Releases
-
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
-
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
-
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
-
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
-
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
-
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
-
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
-
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
-
deCODE genetics: A sequence variant that increases risk of pregnancy loss
-
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
-
Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference
-
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
-
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
-
AMGEN TO SPONSOR THE IRISH OPEN
-
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
-
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
-
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
-
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
-
1 in 25 carries a genotype that is associated with a shortened lifespan
-
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
-
Ligand Reports Third Quarter 2023 Financial Results
-
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
-
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
-
Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition
-
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
-
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
-
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
-
A large international study of migraine reveals new biological pathways for treatment
-
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
-
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
-
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
-
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
-
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023
-
AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023
-
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
-
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS PLC
-
Large-scale proteomics in population-based studies from UK and Iceland
-
AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS
-
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Amgen Inc’s Directors and Officers for Breach of Fiduciary Duties – AMGN
-
Variants in the genome interact with each other and with the environment to affect risk of cardiovascular disease
-
Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023
-
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
-
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC
-
AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE
-
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
-
AMGEN TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE AND THE CITI GLOBAL HEALTHCARE CONFERENCE
-
AMGEN PRESENTS LATE-BREAKING PHASE 2 OLPASIRAN DATA AT ESC 2023
-
AMGEN TO DISCUSS APPLICATION FOR LUMAKRAS® (SOTORASIB) FOR THE TREATMENT OF KRAS G12C-POSITIVE NSCLC AT FDA ADVISORY COMMITTEE MEETING
Back to AMGN Stock Lookup
